BDBM375631 US9908897, Example 8::US9908897, Example 9

SMILES Fc1cccc(Oc2cc(F)cc(c2)N2CCC3(CC2)CNCCO3)c1

InChI Key InChIKey=OZUKNWTZRJTZAM-UHFFFAOYSA-N

Data  7 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 7 hits for monomerid = 375631   

TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  5.62nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  126nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  79.4nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent serotonin transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  100nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent dopamine transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  4.17nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetSodium-dependent noradrenaline transporter(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  123nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent


TargetPotassium voltage-gated channel subfamily H member 2(Human)
Chronos Therapeutics

US Patent
LigandPNGBDBM375631(US9908897, Example 8 | US9908897, Example 9)
Affinity DataIC50:  501nMAssay Description:The affinity of the compounds of the invention to the human DAT or NET or SERT transporters is assessed by using the [3H]WIN-35,428 or [3H]nisoxetine...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent